0 0 0 0 0.000472185332743008 -0.000737789582411096 -0.000147557916482253 -0.00118046333185785
Sign Up Today X
Thanks for submitting the form.
Stockreport

ALMS Surges as Envudeucitinib Meets Goals in Plaque Psoriasis Studies [Yahoo! Finance]

Amgen Inc. (AMGN)  More Company Research Source: Yahoo! Finance
Last amgen inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.amgen.com
ONWARD2 — which evaluated its pipeline candidate, envudeucitinib, for treating patients with moderate-to-severe plaque psoriasis, a chronic autoimmune skin disease. Both the ONWARD1 and ONWARD2 studies met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque psoriasis. Treatment with envudeucitinib led to superior skin clearance versus placebo on the co-primary endpoints of Psoriasis Area and Severity Index (PASI) 75 and static Physician's Global Assessment (sPGA) 0/1 at week 16 in both studies. On average, in the ONWARD1 and ONWARD2 studies, 74% of patients achieved PASI 75 and 59% achieved sPGA 0/1, with responses improving over time. At week 24, across both studies, about 65% of patients achieved PASI 90 and more than 40% achieved PASI 100. Treatment with envudeucitinib was generally well tolerated through week 24 in both the ONWARD1 and ONWARD2 studies. Treatment with envudeucitinib also achieved superior skin cl [Read more]
IMPACT SNAPSHOT EVENT TIME: AMGN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
AMGN alerts
from News Quantified
AMGN
NEWS
AMGN
Earnings
AMGN
Analyst Actions
AMGN
SEC Filings
Stockreport

ALMS Surges as Envudeucitinib Meets Goals in Plaque Psoriasis Studies [Yahoo! Finance]

Amgen Inc.  (AMGN) 
More Company Research Source: Yahoo! Finance
Last amgen inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.amgen.com
ONWARD2 — which evaluated its pipeline candidate, envudeucitinib, for treating patients with moderate-to-severe plaque psoriasis, a chronic autoimmune skin disease. Both the ONWARD1 and ONWARD2 studies met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque psoriasis. Treatment with envudeucitinib led to superior skin clearance versus placebo on the co-primary endpoints of Psoriasis Area and Severity Index (PASI) 75 and static Physician's Global Assessment (sPGA) 0/1 at week 16 in both studies. On average, in the ONWARD1 and ONWARD2 studies, 74% of patients achieved PASI 75 and 59% achieved sPGA 0/1, with responses improving over time. At week 24, across both studies, about 65% of patients achieved PASI 90 and more than 40% achieved PASI 100. Treatment with envudeucitinib was generally well tolerated through week 24 in both the ONWARD1 and ONWARD2 studies. Treatment with envudeucitinib also achieved superior skin cl [Read more]
IMPACT SNAPSHOT
EVENT TIME:
AMGN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS